The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

Xicoy, Blanca; Triguero, Ana; Such, Esperanza; García, Olga; Jiménez, María-José; Arnán, Montserrat; Bernal, Teresa; Díaz‐Beyá, Marina; Valcárcel, David; Pedro, Carme; Ramos, Fernando; Amigo, María‐Luz; Collado, Rosa; Palomo, Laura; Ardanaz, M.; Cedena, María-Teresa; Grau, Javier; Zamora, Lurdes; Sanz, Guillermo

doi:10.1016/j.leukres.2018.05.003

Cited by 16 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we were unable to distinguish differences regarding FAB subtypes within each category, with the exception for a longer OS of 64 months for those patients with CMML-0 and MDS-CMML. Despite evident differences on the distribution toward MDS-CMML-0 patient in the present series, similar limitations were previously observed [24].…”

Section: Discussionsupporting

confidence: 90%

“…Our CMML-0 patients displayed characteristic associated with a better outcome and represent nearly a half of our patients. This proportion was similar to the Spanish dataset [24] but clearly higher than cohorts from the MDACC, whose patients were equally distributed [11], and from Düsseldorf [5]. The proportion of CMML-1 patients also varies among such reports, being lower among our patients (21%) and higher among German patients (53%) [5].…”

Section: Discussionsupporting

confidence: 76%

“…Our results represent the largest CMML series reported so far from Latin America and one of the few attempts to validate the WHO 2016 classification [11,24] and its prognostic capability along with accessible covariates to predict survival. Descriptive and comparative studies are necessary not only to establish epidemiological features useful for public health strategies but also an opportunity for risk stratification to determine prognosis and guide management decisions.…”

Section: Discussionmentioning

confidence: 78%

“…The introduction of CMML-0 as proposed in the WHO 2016 revision is controversial with a heterogeneous distribution of the three subgroups, depending, also, on the criteria considering or not only the percentage of BM blasts [5,11,24]. Our CMML-0 patients displayed characteristic associated with a better outcome and represent nearly a half of our patients.…”

Section: Discussionmentioning

confidence: 86%

See 3 more Smart Citations

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

et al. 2021

View full text Add to dashboard Cite

Knowledge on chronic myelomonocytic leukemia (CMML) patients from Argentina and Brazil is limited. Our series of 280 patients depicted an older age at diagnosis (median 72 years old), 26% of aberrant karyotypes, and a prevalence of myelodysplastic (60%) and CMML-0 subtypes (56%). The median overall survival (OS) was 48.2 months for patients in CMML-0 (Ref.), 24.7 months for those in CMML-1 (HR = 2.0, p = 0.001), and 8.8 months for patients in CMML-2 (HR = 4.6, p < 0.001). In the CMML-0 category, median OS were different between myelodysplastic and myeloproliferative subtypes (63.7 vs 21.2 months, p < 0.001); however, no differences were observed within CMML-1 and CMML-2 subtypes (24.7 vs 23.7 months, p = 0.540, and 9.1 vs 8.2 months, p = 0.160). The prognostic impact of 24 variables and 7 prognostic systems was adjusted to the WHO 2016 after validating their usefulness. Multivariate analysis were performed, and the final model revealed Hb ≥ 8 -< 10g/dL (HR 1.7), Hb < 8g/dL (HR 2.8), poor karyotypes (HR 2.1), WHO 2016-CMML-1 (HR 2.1), and CMML-2 (HR 3.5) as independent adverse clinical parameters in our cohort with a borderline influence of platelets count < 50 × 10 9 /L (HR 1.4). We could validate several scoring systems, the WHO 2016 proposal and its prognostic capability, along with accessible covariates, on predicting the outcome in our series of CMML patients from Latin America.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 86%

See 2 more Smart Citations

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…51 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 52 Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany. ✉ email: jkhoury@unmc.edu; eric.solary@gustaveroussy.fr; andreas.hochhaus@med.uni-jena.de…”

Section: Acknowledgementsmentioning

confidence: 99%

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

et al. 2022

View full text Add to dashboard Cite

The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.

show abstract

References

2021

Flow Cytometry of Hematological Malignancies

View full text Add to dashboard Cite

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

Cited by 16 publications

References 6 publications

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

References

Contact Info

Product

Resources

About